Chandra P. Leo Acquires 10,000 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Director Chandra P. Leo purchased 10,000 shares of Monte Rosa Therapeutics stock in a transaction that occurred on Monday, March 24th. The shares were bought at an average price of $5.84 per share, with a total value of $58,400.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $58,400. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Monte Rosa Therapeutics Stock Down 2.7 %

Shares of Monte Rosa Therapeutics stock traded down $0.16 on Tuesday, hitting $5.67. 681,570 shares of the company were exchanged, compared to its average volume of 938,440. Monte Rosa Therapeutics, Inc. has a 1-year low of $3.21 and a 1-year high of $12.40. The stock has a market capitalization of $348.35 million, a price-to-earnings ratio of -3.10 and a beta of 1.50. The company has a 50-day moving average price of $6.18 and a 200 day moving average price of $6.78.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, March 20th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.60. The company had revenue of $14.00 million during the quarter, compared to analysts’ expectations of $43.73 million. Research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GLUE. Wedbush reissued an “outperform” rating and set a $17.00 target price (up previously from $15.00) on shares of Monte Rosa Therapeutics in a report on Thursday, March 20th. Lifesci Capital assumed coverage on Monte Rosa Therapeutics in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $19.00 price objective for the company. Finally, Wells Fargo & Company lowered their target price on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its holdings in Monte Rosa Therapeutics by 7.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,116,637 shares of the company’s stock valued at $49,391,000 after purchasing an additional 515,496 shares during the last quarter. Versant Venture Management LLC acquired a new stake in shares of Monte Rosa Therapeutics during the 4th quarter worth approximately $39,231,000. Vanguard Group Inc. raised its position in shares of Monte Rosa Therapeutics by 24.5% during the 4th quarter. Vanguard Group Inc. now owns 3,156,354 shares of the company’s stock valued at $21,905,000 after buying an additional 622,134 shares during the period. BVF Inc. IL acquired a new position in Monte Rosa Therapeutics in the fourth quarter valued at approximately $19,185,000. Finally, Geode Capital Management LLC lifted its holdings in Monte Rosa Therapeutics by 23.3% in the third quarter. Geode Capital Management LLC now owns 1,044,689 shares of the company’s stock valued at $5,538,000 after acquiring an additional 197,247 shares during the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.